Dengue vaccine study

By Dylan Bushell-Embling
Tuesday, 02 September, 2008

Avantogen [ASX: ACU] investee Hawaii Biotech will receive clinical trial support from the US Walter Reed Army Institute of Research (WRAIR) for its dengue fever vaccine program.

WRAIR has considerable experience with dengue fever and an established track record in emerging infectious diseases.

The recombinant-DNA-based vaccine candidate will soon undertake the clinical trial process.

Incidents of dengue, a close relative of the West Nile virus, are now growing rapidly in Australia and the Asian region.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd